SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-236970
Filing Date
2021-08-05
Accepted
2021-08-05 07:20:57
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d170530d8k.htm   iXBRL 8-K 30697
2 EX-99.1 d170530dex991.htm EX-99.1 66759
6 GRAPHIC g170530g0805045632942.jpg GRAPHIC 3884
  Complete submission text file 0001193125-21-236970.txt   239295

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aldx-20210805.xsd EX-101.SCH 2887
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20210805_lab.xml EX-101.LAB 18137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20210805_pre.xml EX-101.PRE 11404
7 EXTRACTED XBRL INSTANCE DOCUMENT d170530d8k_htm.xml XML 3362
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 211146297
SIC: 2834 Pharmaceutical Preparations